Japan's Hisamitsu Pharmaceutical Co. Inc. and its U.S. unit Noven Pharmaceuticals Inc. submitted an application seeking U.S. Food and Drug Administration approval for schizophrenia treatment HP-3070.

Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels and behaves.

HP-3070, or asenapine maleate, is a patch placed on the skin to deliver medication into the bloodstream. The transdermal therapy was previously shown to improve symptoms of the disorder in a late-stage study.